First human test for cholesterol drug in people with kidney problems
NCT ID NCT07322016
Summary
This early study aims to understand how a new cholesterol-lowering tablet, HRS-1301, behaves in people with different levels of kidney function compared to healthy people. It will enroll 36 adults with mild, moderate, or severe kidney impairment, as well as healthy volunteers, who will each receive a single dose. The main goal is to gather safety data and see how the drug is processed by the body to help plan future dosing for patients with kidney disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.